Tashinga E. Bapiro

2.9k total citations · 1 hit paper
22 papers, 2.3k citations indexed

About

Tashinga E. Bapiro is a scholar working on Oncology, Pharmacology and Molecular Biology. According to data from OpenAlex, Tashinga E. Bapiro has authored 22 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 9 papers in Pharmacology and 7 papers in Molecular Biology. Recurrent topics in Tashinga E. Bapiro's work include Pancreatic and Hepatic Oncology Research (10 papers), Pharmacogenetics and Drug Metabolism (9 papers) and Drug Transport and Resistance Mechanisms (4 papers). Tashinga E. Bapiro is often cited by papers focused on Pancreatic and Hepatic Oncology Research (10 papers), Pharmacogenetics and Drug Metabolism (9 papers) and Drug Transport and Resistance Mechanisms (4 papers). Tashinga E. Bapiro collaborates with scholars based in United Kingdom, United States and Zimbabwe. Tashinga E. Bapiro's co-authors include Duncan I. Jodrell, David A. Tuveson, Albrecht Neeße, Kristopher K. Frese, Natalie Cook, Martijn P. Lolkema, Frances M. Richards, Tomoaki Nakagawa, Derek Chan and Michael A. Jacobetz and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and PLoS ONE.

In The Last Decade

Tashinga E. Bapiro

21 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer

2012 837 citations Michael A. Jacobetz, Derek Chan et al. Gut profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tashinga E. Bapiro United Kingdom	17	1.6k	808	500	380	251	22	2.3k
Arun Satelli United States	17	1.2k 0.7×	1.2k 1.5×	654 1.3×	520 1.4×	197 0.8×	24	2.5k
Michael Saborowski Germany	16	1.1k 0.7×	968 1.2×	362 0.7×	378 1.0×	224 0.9×	26	2.1k
Yi‐Jun Wang United States	29	1.6k 1.0×	982 1.2×	215 0.4×	646 1.7×	122 0.5×	75	2.5k
Xin Xu China	26	758 0.5×	1.4k 1.8×	709 1.4×	222 0.6×	82 0.3×	84	2.3k
Karuna Ganesh United States	14	1.7k 1.1×	1.4k 1.8×	818 1.6×	828 2.2×	393 1.6×	37	3.4k
Jean‐Pierre Gillet United States	16	876 0.6×	1.0k 1.2×	231 0.5×	115 0.3×	110 0.4×	29	1.7k
Radosław Januchowski Poland	24	736 0.5×	1.1k 1.3×	476 1.0×	224 0.6×	86 0.3×	53	1.8k
Christian M. Kurbacher Germany	27	1.1k 0.7×	724 0.9×	430 0.9×	295 0.8×	124 0.5×	92	2.3k
Klaus Bosslet Germany	30	902 0.6×	1.0k 1.3×	367 0.7×	434 1.1×	81 0.3×	87	2.3k
Monica Tortoreto Italy	32	1.3k 0.8×	2.0k 2.4×	907 1.8×	396 1.0×	159 0.6×	80	3.3k

Countries citing papers authored by Tashinga E. Bapiro

Since Specialization

Citations

This map shows the geographic impact of Tashinga E. Bapiro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tashinga E. Bapiro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tashinga E. Bapiro more than expected).

Fields of papers citing papers by Tashinga E. Bapiro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tashinga E. Bapiro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tashinga E. Bapiro. The network helps show where Tashinga E. Bapiro may publish in the future.

Co-authorship network of co-authors of Tashinga E. Bapiro

This figure shows the co-authorship network connecting the top 25 collaborators of Tashinga E. Bapiro. A scholar is included among the top collaborators of Tashinga E. Bapiro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tashinga E. Bapiro. Tashinga E. Bapiro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bapiro, Tashinga E., Scott Martin, Thomas S. Blacker, et al.. (2025). A mismatch in enzyme-redox partnerships underlies divergent cytochrome P450 activities between human hepatocytes and microsomes. Communications Biology. 8(1). 1539–1539.

Bapiro, Tashinga E., et al.. (2023). The Disconnect in Intrinsic Clearance Determined in Human Hepatocytes and Liver Microsomes Results from Divergent Cytochrome P450 Activities. Drug Metabolism and Disposition. 51(7). 892–901. 6 indexed citations

Ponz‐Sarvisé, Mariano, Vincenzo Corbo, Hervé Tiriac, et al.. (2019). Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer. Clinical Cancer Research. 25(22). 6742–6755. 41 indexed citations

Dandara, Collet, Nicholas Ekow Thomford, & Tashinga E. Bapiro. (2019). Herbal Remedies: Throwing Off Phenotype Prediction—A Culprit for Pharmacogenomic‐Guided Drug Therapy and Drug Safety. Clinical Pharmacology & Therapeutics. 106(2). 302–304. 1 indexed citations

Koh, Siang‐Boon, Yann Wallez, Sandra Bernaldo de Quirós Fernández, et al.. (2018). Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine. Cancer Research. 78(11). 3054–3066. 28 indexed citations

Bapiro, Tashinga E., Scott Martin, Michael Davies, et al.. (2018). Complete Substrate Inhibition of Cytochrome P450 2C8 by AZD9496, an Oral Selective Estrogen Receptor Degrader. Drug Metabolism and Disposition. 46(9). 1268–1276. 16 indexed citations

Heßmann, Elisabeth, Lukas Klein, Vijayalakshmi Kari, et al.. (2017). Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer. Gut. 67(3). 497–507. 148 indexed citations

Gemenetzidis, Emilios, Christine Feig, Tashinga E. Bapiro, et al.. (2016). Anti‐stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma. The Journal of Pathology. 239(3). 286–296. 108 indexed citations

Neeße, Albrecht, Kristopher K. Frese, Derek Chan, et al.. (2013). SPARC independent drug delivery and antitumour effects of nab -paclitaxel in genetically engineered mice. Gut. 63(6). 974–983. 118 indexed citations

10.

Courtin, Aurélie, Frances M. Richards, Tashinga E. Bapiro, et al.. (2013). Anti-Tumour Efficacy of Capecitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer. PLoS ONE. 8(6). e67330–e67330. 32 indexed citations

11.

Neeße, Albrecht, Kristopher K. Frese, Tashinga E. Bapiro, et al.. (2013). CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proceedings of the National Academy of Sciences. 110(30). 12325–12330. 199 indexed citations

12.

Frese, Kristopher K., Albrecht Neeße, Natalie Cook, et al.. (2012). nab -Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer. Cancer Discovery. 2(3). 260–269. 320 indexed citations

13.

Jacobetz, Michael A., Derek Chan, Albrecht Neeße, et al.. (2012). Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 62(1). 112–120. 837 indexed citations breakdown →

14.

Lin, Yao, Frances M. Richards, Jo L. Bramhall, et al.. (2012). Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells. British Journal of Cancer. 107(10). 1692–1701. 28 indexed citations

15.

Bapiro, Tashinga E., Frances M. Richards, Mae A. Goldgraben, et al.. (2011). A novel method for quantification of gemcitabine and its metabolites 2′,2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC–MS/MS: comparison with 19F NMR spectroscopy. Cancer Chemotherapy and Pharmacology. 68(5). 1243–1253. 47 indexed citations

16.

Bapiro, Tashinga E., et al.. (2005). Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans. European Journal of Clinical Pharmacology. 61(10). 755–761. 32 indexed citations

17.

Dandara, Collet, et al.. (2004). Frequency of –163 C > A and 63 C > G single nucleotide polymorphism of cytochrome P450 1A2 in two African populations. Clinical Chemistry and Laboratory Medicine (CCLM). 42(8). 939–41. 15 indexed citations

18.

Bapiro, Tashinga E., Tommy B. Andersson, Charlotta Otter, Julia A. Hasler, & Collen Masimirembwa. (2002). Cytochrome P 450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. European Journal of Clinical Pharmacology. 58(8). 537–542. 24 indexed citations

19.

Bapiro, Tashinga E., Julia A. Hasler, Marianne Ridderström, & Collen Masimirembwa. (2002). The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Biochemical Pharmacology. 64(9). 1387–1398. 34 indexed citations

20.

Bapiro, Tashinga E., Ann‐Charlotte Egnell, Julia A. Hasler, & Collen Masimirembwa. (2001). Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s.. PubMed. 29(1). 30–5. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact